Literature DB >> 29159848

Speech deterioration in amyotrophic lateral sclerosis (ALS) after manifestation of bulbar symptoms.

Tanja Makkonen1,2, Hanna Ruottinen1, Riitta Puhto1, Mika Helminen3,4, Johanna Palmio5.   

Abstract

BACKGROUND: The symptoms and their progression in amyotrophic lateral sclerosis (ALS) are typically studied after the diagnosis has been confirmed. However, many people with ALS already have severe dysarthria and loss of adequate speech at the time of diagnosis. Speech-and-language therapy interventions should be targeted timely based on communicative need in ALS. AIMS: To investigate how long natural speech will remain functional and to identify the changes in the speech of persons with ALS. METHODS & PROCEDURES: Altogether 30 consecutive participants were studied and divided into two groups based on the initial type of ALS, bulbar or spinal. Their speech disorder was evaluated on severity, articulation rate and intelligibility during the 2-year follow-up. OUTCOME &
RESULTS: The ability to speak deteriorated to poor and necessitated augmentative and alternative communication (AAC) methods with 60% of the participants. Their speech remained adequate on average for 18 months from the first bulbar symptom. Severity, articulation rate and intelligibility declined with nearly all participants during the study. To begin with speech deteriorated more in the bulbar group than in the spinal group and the difference remained during the whole follow-up with some exceptions. CONCLUSIONS & IMPLICATIONS: The onset of bulbar symptoms indicated the time to loss of speech better than when assessed from ALS diagnosis or the first speech therapy evaluation. In clinical work, it is important to take the initial type of ALS into consideration when determining the urgency of AAC measures as people with bulbar-onset ALS are more susceptible to delayed evaluation and AAC intervention.
© 2017 Royal College of Speech and Language Therapists.

Entities:  

Keywords:  amyotrophic lateral sclerosis (ALS); bulbar symptoms; motor speech disorder

Mesh:

Year:  2017        PMID: 29159848     DOI: 10.1111/1460-6984.12357

Source DB:  PubMed          Journal:  Int J Lang Commun Disord        ISSN: 1368-2822            Impact factor:   3.020


  10 in total

1.  Decoding spoken English from intracortical electrode arrays in dorsal precentral gyrus.

Authors:  Guy H Wilson; Sergey D Stavisky; Francis R Willett; Donald T Avansino; Jessica N Kelemen; Leigh R Hochberg; Jaimie M Henderson; Shaul Druckmann; Krishna V Shenoy
Journal:  J Neural Eng       Date:  2020-11-25       Impact factor: 5.379

2.  Validation of Articulatory Rate and Imprecision Judgments in Speech of Individuals With Amyotrophic Lateral Sclerosis.

Authors:  Ashley A Waito; Farah Wehbe; Reeman Marzouqah; Carolina Barnett; Sanjana Shellikeri; Cindy Cui; Agessandro Abrahao; Lorne Zinman; Jordan R Green; Yana Yunusova
Journal:  Am J Speech Lang Pathol       Date:  2020-12-08       Impact factor: 2.408

3.  A Cross-Sectional, Quantitative Videofluoroscopic Analysis of Swallowing Physiology and Function in Individuals With Amyotrophic Lateral Sclerosis.

Authors:  Ashley A Waito; Emily K Plowman; Carly E A Barbon; Melanie Peladeau-Pigeon; Lauren Tabor-Gray; Kelby Magennis; Raele Robison; Catriona M Steele
Journal:  J Speech Lang Hear Res       Date:  2020-04-18       Impact factor: 2.297

Review 4.  Clinical Measures of Bulbar Dysfunction in ALS.

Authors:  Yana Yunusova; Emily K Plowman; Jordan R Green; Carolina Barnett; Peter Bede
Journal:  Front Neurol       Date:  2019-02-19       Impact factor: 4.003

5.  Detection of Bulbar Involvement in Patients With Amyotrophic Lateral Sclerosis by Machine Learning Voice Analysis: Diagnostic Decision Support Development Study.

Authors:  Francesc Solsona; Alberto Tena; Francec Claria; Einar Meister; Monica Povedano
Journal:  JMIR Med Inform       Date:  2021-03-10

6.  Detecting Bulbar Involvement in Patients with Amyotrophic Lateral Sclerosis Based on Phonatory and Time-Frequency Features.

Authors:  Alberto Tena; Francesc Clarià; Francesc Solsona; Mònica Povedano
Journal:  Sensors (Basel)       Date:  2022-02-02       Impact factor: 3.576

7.  Overcoming therapeutic nihilism. Breaking bad news of amyotrophic lateral sclerosis-a patient-centred perspective in rare diseases.

Authors:  Stanisław Maksymowicz; Maria Libura; Paulina Malarkiewicz
Journal:  Neurol Sci       Date:  2022-02-12       Impact factor: 3.830

8.  Rate of speech decline in individuals with amyotrophic lateral sclerosis.

Authors:  Marziye Eshghi; Yana Yunusova; Kathryn P Connaghan; Bridget J Perry; Marc F Maffei; James D Berry; Lorne Zinman; Sanjay Kalra; Lawrence Korngut; Angela Genge; Annie Dionne; Jordan R Green
Journal:  Sci Rep       Date:  2022-09-20       Impact factor: 4.996

Review 9.  Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics?

Authors:  Bradley Roberts; Frances Theunissen; Francis L Mastaglia; P Anthony Akkari; Loren L Flynn
Journal:  Int J Mol Sci       Date:  2022-08-19       Impact factor: 6.208

10.  Early detection and tracking of bulbar changes in ALS via frequent and remote speech analysis.

Authors:  Gabriela M Stegmann; Shira Hahn; Julie Liss; Jeremy Shefner; Seward Rutkove; Kerisa Shelton; Cayla Jessica Duncan; Visar Berisha
Journal:  NPJ Digit Med       Date:  2020-10-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.